CathWorks (acquired by Medtronic)
About CathWorks (acquired by Medtronic)
CathWorks is a medical technology company that has developed an AI-powered, non-invasive imaging software called the FFRangio® System, designed to optimize therapy decisions for coronary artery disease (CAD). The system utilizes artificial intelligence and advanced computational science to obtain physiological information directly from routine coronary angiograms, eliminating the need for invasive pressure wires and pharmacologic stimulation. This provides physicians with quick and reliable fractional flow reserve (FFR) values for the entire coronary tree, offering a comprehensive physiological assessment.
The FFRangio System aims to elevate coronary angiography from a visual assessment to an objective FFR-based decision-making tool. This approach is supported by clinical evidence, including the landmark ALL-RISE randomized control trial, which demonstrated that CathWorks FFRangio is non-inferior to wire-based physiology in terms of major adverse cardiac events (MACE) at one year, while also improving resource utilization and reducing procedure time. The technology assists physicians in identifying which lesions truly cause ischemia, enabling appropriate revascularization and potentially avoiding unnecessary percutaneous coronary intervention (PCI). Medtronic acquired CathWorks in April 2026, integrating this innovative technology into its cardiovascular portfolio to transform care for patients with CAD.
Focus Areas
Business Intelligence
| Technology | AI and advanced computational science platform that analyzes routine coronary angiograms to produce 3D models and physiological assessments of blood flow (FFR values) along the entire coronary tree. |
What Physicians Need to Know
For physicians, CathWorks' FFRangio® System streamlines workflow by eliminating the need for invasive pressure wires and drug stimulation, offering a faster and less invasive method for comprehensive physiological assessment. It provides real-time FFRangio values across the entire coronary tree, a simulated pullback curve to differentiate functional patterns of CAD, and a lesion impact tool to evaluate the clinical significance of lesions. This allows for optimized clinical decision-making, more precise stent placement, and improved patient comfort.
The CathWorks FFRangio® System is designed for seamless integration with existing cath lab infrastructure, including the boom and PACS.
What the Web Says
CathWorks, acquired by Medtronic in April 2026, is a medical device company specializing in an AI-powered system called FFRangio for diagnosing and treating coronary artery disease. The system offers a non-invasive, wire-free approach to assess coronary physiology, differing from traditional methods that use pressure wires and pharmacologic hyperemia. While specific product reviews from G2, Glassdoor, and Capterra are not readily available, the acquisition by Medtronic and the positive clinical trial results suggest a strong market reception and potential for transforming cardiovascular care.
Overall: PositiveStrengths
- FFRangio System provides a comprehensive physiological assessment of the entire coronary tree using routine angiograms.
- The system is drug-free and wire-free, offering a less invasive alternative to traditional FFR assessment.
- It utilizes AI and advanced computational science for quick and reliable fractional flow reserve (FFR) values.
- Clinical trials have shown non-inferiority to wire-based physiology for major adverse cardiac events at one year, with improved resource utilization and reduced procedure time.
- The technology has the potential to transform the cath lab by providing real-time data and informing individualized treatment approaches.
- Medtronic's acquisition and prior co-promotion indicate confidence in the technology and its market potential.
Limitations
- Specific negative product reviews from independent platforms like G2, Capterra, or healthcare IT reviewers are not readily available in the search results.
- Detailed employee reviews for CathWorks specifically (pre-acquisition) are limited, with Glassdoor showing a 3.6 rating for Medtronic, which now encompasses CathWorks.
- The transition and integration into a larger company like Medtronic could present challenges, as noted by CathWorks' CEO regarding potential issues with product development post-acquisition.
Based on reviews from: Swooped, Medical Design & Outsourcing, Medtronic, Indeed.com, MedTech Dive, Reddit, PR Newswire, Investing.com, Cardiovascular News, MassDevice, YouTube, Signify Research, Goodwin, Investing News Network, MarketScreener UK
Last updated: 2026-10-21
Videos
News, demos, and interviews about CathWorks (acquired by Medtronic).
Videos load interactively. If none appear, search YouTube for CathWorks (acquired by Medtronic) →
Press & Coverage
Frequently Asked Questions
Comparisons
Related Companies
Surgical Reality is a healthcare AI company that specializes in advanced AI-powered 3D medical imaging and surgical planning software for thoracic surgery. Their core product, the Surgical Reality Viewer, converts standard CT scans into high-fidelity, patient-specific 3D models of the entire lung within minutes. This technology is designed to assist trained healthcare professionals with preoperative […]
Meril Life Sciences is an Indian multinational medical device company dedicated to the innovation, design, and development of clinically relevant and state-of-the-art devices. The company focuses on alleviating human suffering and improving the quality of life through advanced healthcare solutions. Meril’s extensive product portfolio spans various medical fields, including vascular intervention, orthopedic implants, robotics, endosurgery, […]
Caption Health, formerly known as Bay Labs and now part of GE HealthCare, is a pioneering medical artificial intelligence (AI) company dedicated to expanding access to high-quality ultrasound examinations. The company’s core offering is the Caption AI platform, which utilizes AI to guide healthcare providers, including those without extensive specialized training, in acquiring and interpreting […]
Anumana is an AI-driven health technology company dedicated to transforming cardiovascular care. Co-founded by nference and Mayo Clinic, Anumana develops software-as-a-medical-device (SaMD) solutions that leverage multimodal AI to support early detection, clinical decision-making, and intraoperative guidance across the continuum of care. The company’s portfolio includes FDA-cleared ECG-based algorithms, generative imaging applications, and real-time procedural support […]
Keya Medical Technology Co. is an international medical technology company specializing in deep learning-based AI solutions for non-invasive disease diagnosis and treatment. The company, founded in 2016, develops AI-enabled diagnostic devices that aim to enhance efficiency, accuracy, and precision in healthcare across various specialties, including cardiology, neurology, pulmonology, pathology, and surgery. [2, 4, 8, 14] […]
Siemens Medical Solutions USA, Inc., operating as Siemens Healthineers USA, is a prominent medical technology company with a rich history spanning over 175 years, dedicated to pioneering breakthroughs in healthcare. As a subsidiary of the global Siemens Healthineers AG, the company offers a comprehensive portfolio that is central to clinical decision-making across the entire healthcare […]